Print Page | Contact Us | Sign In | Join
Industry News: News

Neurotoxin News: The DAXI Differentiator

Monday, May 13, 2019   (0 Comments)
Share |

By all accounts, Revance is preparing for the FDA’s approval and market launch of its lead compound daxibotulinumtoxinA for injection (DAXI). DAXI clinical trials looking at glabellar line treatment suggest the neuromodulator with its proprietary peptide technology is at least as good as Botox (onabotulinumtoxinA, Allergan) but lasts substantially longer.

On April 9, Revance announced former Allergan marketing professional Taryn Conway had joined the biotechnology company’s team “… as the company transitions from clinical-stage development to commercialization…,” according to a Revance press release.

Read more at Dermatology Times >>

Contact Us

224 N Desplaines, Ste. 600S
 Chicago, IL 60661

Phone: 312-981-0993

Fax: 888-827-8860


AmSpa provides legal, compliance, and business resources for medical spas and medical aesthetic practices.

Follow Us: